Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Human Papillomavirus Genotype Distribution and E6/E7 Oncogene Expression in Turkish Women with Cervical Cytological Findings

  • Tezcan, Seda (Department of Medical Microbiology, Faculty of Medicine, Mersin University) ;
  • Ozgur, Didem (Department of Medical Microbiology, Faculty of Medicine, Mersin University) ;
  • Ulger, Mahmut (Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Mersin University) ;
  • Aslan, Gonul (Department of Medical Microbiology, Faculty of Medicine, Mersin University) ;
  • Gurses, Iclal (Department of Pathology, Faculty of Medicine, Mersin University) ;
  • Serin, Mehmet Sami (Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Mersin University) ;
  • Giray, Burcu Gurer (Department of Medical Microbiology, Faculty of Medicine, Mersin University) ;
  • Dilek, Saffet (Department of Obstetric and Gynecology, Faculty of Medicine, Mersin University) ;
  • Emekdas, Gurol (Department of Medical Microbiology, Faculty of Medicine, Mersin University)
  • Published : 2014.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Infection with certain human papillomavirus (HPV) genotypes is the most important risk factor related with cervical cancer. The objective of the present study was to investigate the prevalence of HPV infection, the distribution of HPV genotypes and HPV E6/E7 oncogene mRNA expression in Turkish women with different cervical cytological findings in Mersin province, Southern Turkey. Materials and Methods: A total of 476 cytological samples belonging to women with normal and abnormal cervical Pap smears were enrolled in the study. For the detection and genotyping assay, a PCR/direct cycle sequencing approach was used. E6/E7 mRNA expression of HPV-16, 18, 31, 33, and 45 was determined by type-specific real-time NASBA assay (NucliSENS EasyQ$^{(R)}$HPV v1.1). Results: Of the 476 samples, 106 (22.3%) were found to be positive for HPV DNA by PCR. The presence of HPV was significantly more common (p<0.001) in HSIL (6/8, 75%) when compared with LSIL (6/14, 42.9%), ASC-US (22/74, 29.7%) and normal cytology (72/380, 18.9%). The most prevalent genotypes were, in descending order of frequency, HPV genotype 66 (22.6%), 16 (20.8%), 6 (14.2%), 31 (11.3%), 53 (5.7%), and 83 (4.7%). HPV E6/E7 oncogene mRNA positivity (12/476, 2.5%) was lower than DNA positivity (38/476, 7.9%). Conclusions: Our data present a wide distribution of HPV genotypes in the analyzed population. HPV genotypes 66, 16, 6, 31, 53 and 83 were the predominant types and most of them were potential carcinogenic types. Because of the differences between HPV E6/E7 mRNA and DNA positivity, further studies are required to test the role of mRNA testing in the triage of women with abnormal cervical cytology or follow up of HPV DNA positive and cytology negative. These epidemiological data will be important to determine the future impact of vaccination on HPV infected women in our region.

Keywords

References

  1. Abike F, Bingol B, Yilmaz A, et al (2013). HPV Infection and HPV Subtypes in Normal and Abnormal Cervical Cytology in Turkish Women. J Virology & Microbiology, 640873.
  2. Akcali S, Goker A, Ecemis T, Kandiloglu AR, Sanlidag T (2013). Human papilloma virus frequency and genotype distribution in a Turkish population. Asian Pac J Cancer Prev, 14, 503-6. https://doi.org/10.7314/APJCP.2013.14.1.503
  3. Batmaz G, Cetin A, Dane C, Gorgen H, Dane B (2009). HPV DNA positivity in women with normal and abnormal cervical smears. Turk J Gynecol Oncol, 1, 10-4.
  4. Benevolo M, Terrenato I, Mottolese M, et al (2011). Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients. Cancer Causes Control, 22, 869-75. https://doi.org/10.1007/s10552-011-9757-0
  5. Bosch FX, Broker TR, Forman D, et al (2013). Comprehensive control of human papillomavirus infections and related diseases. Vaccine, 31, 1-31. https://doi.org/10.1016/j.vaccine.2013.10.003
  6. Chen Q, Luo ZY, Lin M, et al (2012). Prevalence and genotype distribution of human papillomavirus infections in women attending hospitals in Chaozhou of Guangdong province. Asian Pac J Cancer Prev, 13, 1519-24. https://doi.org/10.7314/APJCP.2012.13.4.1519
  7. Ciesielska U, Nowi.ska K, Podhorska-Okolow M, Dziegiel P (2012). The role of human papillomavirus in the malignant transformation of cervix epithelial cells and the importance of vaccination against this virus. Adv Clin Exp Med, 21, 235-44.
  8. Coutlee F, Rouleau D, Ferenczy A, Franco E (2005). The laboratory diagnosis of genital human papillomavirus infections. Can J Infect Dis Med Microbiol, 16, 83-91.
  9. Doorbar J, Quint W, Banks L, et al (2012). The biology and life-cycle of human papillomaviruses. Vaccine, 30, 55-70. https://doi.org/10.1016/j.vaccine.2012.06.083
  10. Dursun P, Ayhan A, Mutlu L, et al (2013). HPV types in Turkey: multicenter hospital based evaluation of 6388 patients in Turkish gynecologic oncology group centers. Turk Patoloji Derg, 29, 210-6.
  11. Ergunay K, Misirlioglu M, Firat P, et al (2008). Detection and typing of human papilloma virus by polymerase chain reaction and hybridization assay in cervical samples with cytological abnormalities. Mikrobiyol Bul, 42, 273-82.
  12. Evander M, Edlund K, Gustafsson A, et al (1995). Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis, 171, 1026-30. https://doi.org/10.1093/infdis/171.4.1026
  13. Gibb RK, Martens MG (2011). The impact of liquid-based cytology in decreasing the incidence of cervical cancer. Rev Obstet Gynecol, 4, 2-11.
  14. Giorgi Rossi P, Benevolo M, Vocaturo A, et al (2013). Prognostic value of HPV E6/E7 mRNA assay in women with negative colposcopy or CIN1 histology result: a follow-up study. PLoS One, 8, 57600. https://doi.org/10.1371/journal.pone.0057600
  15. Guan P, Howell-Jones R, Li N, et al (2012). Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer, 131, 2349-59. https://doi.org/10.1002/ijc.27485
  16. Hamzi Abdul Raub S, Isa NM, Zailani HA, et al (2014). Distribution of HPV genotypes in cervical cancer in multi- ethnic Malaysia. Asian Pac J Cancer Prev, 15, 651-6. https://doi.org/10.7314/APJCP.2014.15.2.651
  17. Jastreboff AM, Cymet T (2002). Role of the human papilloma virus in the development of cervical intraepithelial neoplasia and malignancy. Postgrad Med J, 78, 225-8. https://doi.org/10.1136/pmj.78.918.225
  18. Jeantet D, Schwarzmann F, Tromp J, et al (2009). NucliSENS EasyQ HPV v1 test - Testing for oncogenic activity of human papillomaviruses. J Clin Virol, 45, 29-37. https://doi.org/10.1016/S1386-6532(09)70006-X
  19. Kitchener HC, Denton K, Soldan K, Crosbie EJ (2013). Developing role of HPV in cervical cancer prevention. BMJ, 347, 4781. https://doi.org/10.1136/bmj.f4781
  20. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM (2011). Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer, 128, 927-35. https://doi.org/10.1002/ijc.25396
  21. Lin CY, Chen HC, Lin RW, et al (2007). Quality assurance of genotyping array for detection and typing of human papillomavirus. J Virol Methods, 140, 1-9. https://doi.org/10.1016/j.jviromet.2006.10.004
  22. Lin CY, Chao A, Yang YC, et al (2008). Human papillomavirus typing with a polymerase chain reaction-based genotyping array compared with type-specific PCR. J Clin Virol, 42, 361-7. https://doi.org/10.1016/j.jcv.2008.03.018
  23. Manos MM, Wright DK, Lewis AJ, Broker TR, Wolinsky SM (1989). The use of polymerase reaction amplification for the detection of genital human papillomaviruses. Cancer Cells, 7, 209-14.
  24. Meijer CJ, Snijders PJ, Castle PE (2006). Clinical utility of HPV genotyping. Gynecol Oncol, 103, 12-7. https://doi.org/10.1016/j.ygyno.2006.07.031
  25. Munoz N, Bosch FX, de Sanjose S, et al (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 348, 518-27. https://doi.org/10.1056/NEJMoa021641
  26. Munoz N, Bosch FX, Castellsague X, et al (2004). Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer, 111, 278-85. https://doi.org/10.1002/ijc.20244
  27. Natphopsuk S, Settheetham-Ishida W, Pientong C, et al (2013). Human papillomavirus genotypes and cervical cancer in northest Thailand. Asian Pac J Cancer Prev, 14, 6961-4. https://doi.org/10.7314/APJCP.2013.14.11.6961
  28. Ozturk S, Kaleli I, Kaleli B, Bir F (2004). Investigation of human papillomavirus DNA in cervical specimens by hybrid capture assay. Mikrobiyol Bul, 38, 223-32.
  29. Pannier-Stockman C, Segard C, Bennamar S, et al (2008). Prevalence of HPV genotypes determined by PCR and DNA sequencing in cervical specimens from French women with or without abnormalities. J Clin Virol, 42, 353-60. https://doi.org/10.1016/j.jcv.2008.03.022
  30. Ronco G, Giorgi Rossi P (2008). New paradigms in cervical cancer prevention: opportunities and risks. BMC Womens Health, 8, 23. https://doi.org/10.1186/1472-6874-8-23
  31. Sahiner F, Kubar A, Yapar M, et al (2014). Detection of major HPVs by a new multiplex real-time PCR assay using type-specific primers. J Microbiol Methods, 97, 44-50. https://doi.org/10.1016/j.mimet.2013.12.012
  32. Shen-Gunther J, Yu X (2011). HPV molecular assays: defining analytical and clinical performance characteristics for cervical cytology specimens. Gynecol Oncol, 123, 263-71. https://doi.org/10.1016/j.ygyno.2011.07.017
  33. Schiffman M, Herrero R, Desalle R, et al (2005). The carcinogenicity of human papillomavirus types reflects viral evolution. Virology, 337, 76-84. https://doi.org/10.1016/j.virol.2005.04.002
  34. Snijders PJ, van den Brule AJ, Schrijnemakers HF, et al (1990). The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol, 71, 173-81. https://doi.org/10.1099/0022-1317-71-1-173
  35. Spathis A, Kottaridi C, Chranioti A, et al (2012). mRNA and DNA detection of human papillomaviruses in women of all ages attending two colposcopy clinics. PLoS One, 7, 49205. https://doi.org/10.1371/journal.pone.0049205
  36. Speich N, Schmitt C, Bollmann R, Bollmann M (2004). Human papillomavirus (HPV) study of 2916 cytological samples by PCR and DNA sequencing: genotype spectrum of patients from the west German area. J Med Microbiol, 53, 125-8. https://doi.org/10.1099/jmm.0.05447-0
  37. Turki R, Sait K, Anfinan N, Sohrab SS, Abuzenadah AM (2013). Prevalence of human papillomavirus in women from Saudi Arabia. Asian Pac J Cancer Prev, 14, 3177-81. https://doi.org/10.7314/APJCP.2013.14.5.3177
  38. Villa LL, Denny L (2006). Methods for detection of HPV infection and its clinical utility. Int J Gynaecol Obstet, 94, 71-80. https://doi.org/10.1016/S0020-7292(07)60013-7
  39. Wang L, Dai SZ, Chu HJ, Cui HF, Xu XY (2013). Integration sites and genotype distributions of human papillomavirus in cervical intraepithelial neoplasia. Asian Pac J Cancer Prev, 14, 3837-41. https://doi.org/10.7314/APJCP.2013.14.6.3837
  40. Yildirim D, Yildirim ME, Bakici MZ (2013). Human papillomavirus positivity and frequency of genotypes in servical samples of women living in Sivas Region. Firat Med J, 18, 94-97.
  41. Yuce K, Pinar A, Salman MC, et al (2012). Detection and genotyping of cervical HPV with simultaneous cervical cytology in Turkish women: a hospital-based study. Arch Gynecol Obstet, 286, 203-8. https://doi.org/10.1007/s00404-012-2280-z

Cited by

  1. TLR9 Expression in Uterine Cervical Lesions of Uyghur Women Correlate with Cervical Cancer Progression and Selective Silencing of Human Papillomavirus 16 E6 and E7 Oncoproteins in Vitro vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5867
  2. Performance of HPV DNA Testing with Hybrid Capture 2 in Triaging Women with Minor Cervical Cytologic Abnormalities (ASC-US/LSIL) in Northern Thailand vol.15, pp.24, 2014, https://doi.org/10.7314/APJCP.2014.15.24.10961
  3. Prevalence of Human Papillomavirus Types and Phylogenetic Analysis of HPV-16 L1 Variants from Southern India vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.2073
  4. Update knowledge on cervical cancer incidence and prevalence in Asia vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3617
  5. Assessment of human papillomavirus E6/E7 oncogene expression as cervical disease biomarker vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2885-x
  6. The clinical performance of computer-assisted liquid-based cytology, primary hrHPV screening, and cotesting at a Turkish Tertiary Care Hospital vol.46, pp.1, 2018, https://doi.org/10.1002/dc.23836
  7. Prevalence of high-risk human papilloma virus in liquid-based cervical samples from Turkish women with normal and abnormal cytology pp.87551039, 2018, https://doi.org/10.1002/dc.24022